From:  Short-term outcomes after implementation of SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen within primary care
 

Inclusion and exclusion criteria used to identify participants in the study

Inclusion criteriaExclusion criteria

  • Moderately severe asthmatics

  • Aged 12 and above

  • On ICS/LABA therapy

  • On ICS dose < 800 mcg BDP equivalent

  • Mild asthmatics

  • Aged below 12 years old

  • On SABA only, ICS only or ICS/LABA/LAMA

  • Asthma COPD overlap

  • Asthmatics with ILD

  • On ICS dose > 800 mcg BDP equivalent

Return to article view

ICS: inhaled corticosteroid; LABA: long-acting beta-agonist; SABA: short-acting β2-agonist; LAMA: long-acting muscarinic antagonist; BDP: beclomethasone dipropionate; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease